News

Lung Exacerbations in Young CF Patients Linked to Poorer Quality of Life

Pulmonary exacerbations have a negative impact on the general health-related quality of life in people with cystic fibrosis (CF), a study reported, stressing the importance of preventing such flares in this group. Assessing general, as opposed to disease-specific, health-related quality of life measures are needed when comparing different disease conditions and determining the usefulness of…

Pilot Program to Help CF Families Navigate Care Systems Reports Initial Success

ACT.md recently reported positive preliminary results from a multiyear project — in partnership with Boston Medical Center and Baystate Health — using the company’s “Collaborative Consultative Care Coordination Program” (4C) to measure improvements in quality of life, family engagement, and healthcare costs for children affected by medically complex conditions like cystic fibrosis. First results…

European Medicines Panel Favors ‘Orphan Product’ Designation for Drug to Treat CF Lung Infections

The European Medicines Authority’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending the designation of orphan medicinal product to Arch Biopartners Inc.‘s AB569 as a potential treatment of infections in cystic fibrosis (CF) patients. AB569 was invented at the University of Cincinnati (UC) in the laboratory…

Natural Treatments of Little Benefit on Their Own to CF Patients, But Potential Seen for Drug Development

A Chicago Medical School review explored the scientific evidence behind three natural compounds — genistein, curcumin, and resveratrol — often proposed for the treatment of cystic fibrosis (CF). The review concluded that while the mechanisms by which these substances function should be further investigated as potential drug treatments, there is little evidence…

Pulmatrix CEO Gives Overview of Advances, Both Current and In-Development, in Ways of Treating CF Lung Infections

Pulmatrix, Inc.’s chief scientific officer, Dr. David L. Hava, described in an article recent advances in drug delivery strategies — such as nebulizers for inhaled delivery  — that are helping to treat bacterial and fungal lung infections, and are particularly relevant to people with diseases like cystic fibrosis (CF). The article, “…

AmpliPhi Presents Data on Cystic Fibrosis Drug AB-PA01 at European Meeting

AmpliPhi Biosciences, a biotech company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, recently presented new data at the European Congress of Clinical Microbiology and Infectious Diseases about the in vitro and in vivo activity of its investigational phage mix AB-PA01. Chronic lung infections caused by Pseudomonas aeruginosa are a major…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.